RECURRENT NSCLC

Clinical trials for RECURRENT NSCLC explained in plain language.

Never miss a new study

Get alerted when new RECURRENT NSCLC trials appear

Sign up with your email to follow new studies for RECURRENT NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets hard-to-treat cancers with KRAS and BRAF mutations

Disease control Recruiting now

This study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…

Matched conditions: RECURRENT NSCLC

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

RECURRENT NSCLC

Get alerted when new RECURRENT NSCLC trials appear

New pill targets hard-to-treat cancers with KRAS and BRAF mutations